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1344Objective:Molecular diagnostics capable of prognosticating disease recurrence in stage I non–small cell lung
cancer (NSCLC) patients have implications for improving survival. The objective of the present study was to
develop a multianalyte serum algorithm predictive of disease recurrence in stage I NSCLC patients.
Methods: The Luminex immunobead platform was used to evaluate 43 biomarkers against 79 patients with re-
sectable NSCLC, with the following cohorts represented: stage I (T1-T2N0M0) NSCLC without recurrence
(n ¼ 37), stage I (T1-T2N0M0) NSCLC with recurrence (n ¼ 15), and node-positive (T1-T2N1-N2M0) NSCLC
(n ¼ 27). Peripheral blood was collected before surgery, with all patients undergoing anatomic resection. Uni-
variate statistical methods (receiver operating characteristics curves and log-rank test) were used to evaluate
each biomarker with respect to recurrence and outcome. Multivariate statistical methods were used to develop
a prognostic classification panel for disease recurrence.
Results: No relationship was found between recurrence and age, gender, smoking history, or histologic type.
Analysis for all stage I patients revealed 28 biomarkers significant for recurrence. Of these, the log-rank test
identified 10 biomarkers that were strongly (P<.01) prognostic for recurrence. The Random Forest algorithm
created a 6-analyte panel for preoperative classification that accurately predicted recurrence in 77% of stage I
patients tested, with a sensitivity of 74% and specificity of 79%.
Conclusions:We report the development of a serum biomarker algorithm capable of preoperatively predict-
ing disease recurrence in stage I NSCLC patients. Refinement of this panel might stratify patients for
adjuvant therapy or aggressive recurrence monitoring to improve survival. (J Thorac Cardiovasc Surg
2012;144:1344-51)The American Cancer Society has estimates more than
226,160 new cases of lung cancer, along with approximately
160,340 deaths, in 2012, making it the most common cause
of malignancy-related mortality in the United States.1 Non–
small cell lung cancer (NSCLC) is particularly lethal, be-
cause many patients present with regional (lymph node) or
distant metastases, which has been associated with 24%
and 4% 5-year survival, respectively.1,2 In contrast, as
much as 20% of patients with stage I disease will die of
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The Journal of Thoracic and Cardiovascular SurRecurrence in this group suggests that systemic tumor
cell dissemination (locoregional or distant) had already
occurred at surgery but was undetected by current clinical
and pathologic staging practices.3,4 This group of patients
with occult ‘‘micrometastatic’’ disease will only receive
postoperative surveillance as the standard of care, although
these patients might experience substantial clinical benefit
from more frequent postoperative surveillance and/or
adjuvant systemic chemotherapy (similar to higher stage
groups), if appropriate methods were available for
definitive selection. The increased use of chest computed
tomography (CT) screening protocols in the next several
years is expected to shift NSCLC staging demographics
toward stage I disease, given the preliminary data from the
National Lung Screening Trial, demonstrating a 20%
reduction in mortality from NSCLC with screening of
high-risk patients relative to chest radiography.5 Methods
to definitively select stage I patients are urgently needed to
help direct patients likely to benefit from adjuvant chemo-
therapy into prospective clinical trials and to assist with
the management of the anticipated increased numbers of
stage I NSCLC cases resulting from the implementation of
low-dose CT screening protocols.
The objective of the present studywas to develop a simple
and cost-effective serum test that is prognostic for diseasegery c December 2012
Abbreviations and Acronyms
CT ¼ computed tomography
IGFBP ¼ insulin-like growth factor binding protein
NSCLC ¼ non–small cell lung cancer
OOB ¼ out-of-bag
PDIA3 ¼ protein disulfide isomerase 3
PET ¼ positron emission tomography
TIMP ¼ tissue inhibitor of metalloproteinase
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Srecurrence in stage I NSCLC patients. For this effort, we
reasoned that biomarkers we had reported in our previous
studies6-9 as efficacious for identifying patients with
locoregional disease progression might also have utility in
predicting recurrence in the stage I cohort. We based this
hypothesis on the premise that occult micrometastases are
the primary cause of disease recurrence in these cases,
thereby providing a common mechanistic foundation
to investigate. The resulting prognostic classification
algorithm represents an exciting advancement in our
ability to individualize treatment for stage I NSCLC
patients.PATIENTS AND METHODS
Between 2004 and 2008, we enrolled 79 patients who were divided into
the following cohorts: stage I (T1-T2N0M0) NSCLC without recurrence
(n ¼ 37), stage I (T1-T2N0M0) NSCLC with recurrence (n ¼ 15), and
node-positive (T1-T2N1-N2M0) NSCLC (n ¼ 27). All staging presented
was from the pathologic evaluations. The patient inclusion criteria in-
cluded NSCLC disease confined to the chest without evidence of distant
metastases; no preoperative chemo- or radiotherapy within 1 year of our
initial blood sampling; and a minimum of 2 years of clinical follow-up
data. Patients who died perioperatively were excluded, because they
would not have had sufficient follow-up to determine their recurrence sta-
tus. Demographic information is listed in Table 1. All patient data were
acquired with written formal consent and in absolute compliance with
the institutional review board at Rush University Medical Center
(Chicago, Ill).
Clinical workup at our institution for all NSCLC patients includes CTof
the chest and/or abdomen and positron emission tomography (PET). Pa-
tients with evidence of possible mediastinal lymph node involvement
were evaluated by mediastinoscopy before any additional surgical inter-
vention. All patients with negative findings for mediastinal lymph node in-
volvement on CT-PET scanning or with negative mediastinoscopy findings
underwent complete anatomic resection with lymph node dissection of the
hilar and/or mediastinal nodes. All intraoperative specimens were exam-
ined at surgery by pathologists within our institution to determine margin
involvement and potential regional metastatic disease. Routine pathologic
examination included hematoxylin and eosin permanent stains on all surgi-
cally removed tissue samples with immunohistochemical analysis per-
formed as indicated to confirm disease origin. All samples denoted as
lymph node negative had no evidence of metastases or micrometastases
on complete pathologic evaluation.
Measurement of Serum Biomarker Concentrations
Serum was prepared using standard phlebotomy protocols from periph-
eral blood collected in red-top tubes immediately before pulmonaryThe Journal of Thoracic and Carresection. All specimens were processed within 1 hour of collection,
with 50 mL/mL added to the serum aliquots before archiving at80C.
No specimen was subjected to more than 2 freeze–thaw cycles before
immunoassay evaluation. Assays for insulin-like growth factor binding
proteins (IGFBPs) 1 to 7, interferon-g, CA19-9, cytokeratin 19 fragment
21-1, stem cell factor-1, stromal cell-derived factor-1a, monocyte
colony-stimulating factor, interleukin-2Ra, tissue inhibitor of metallopro-
teinase (TIMP)-1, and IGF-1 were performed using Milliplex Map Kits
(EMD-Millipore, Billerica, Mass). The assays used for the circulating au-
toantibody biomarkers were identical to our previously described
methods.6-9 All biomarker concentrations were calculated using
a 5-parametric curve fit using xPONENT, version 4.03 (Luminex Corp,
Austin, Tex) in a blinded fashion with measurement performed with the
FlexMAP 3D system (Luminex Corp). Table 2 lists the 43 biomarkers
evaluated in the present study.
The methods for candidate biomarker testing were identical to those
previously reported.6-9 In brief, we selected biomarkers for the present
study using 2 methods. The first was from a review of the published data
for biomarkers that had previously demonstrated efficacy for the early
detection of lung cancer.6 The second was based on previous efforts in
our laboratory.8 Specifically, we used Western blots prepared using lysates
from a lung adenocarcinoma cell line (HCC827) that were then probedwith
pooled serum from 2 NSCLC patients groups, the first without nodal in-
volvement and the second with node-positive disease. We compared the
immunoblots and performed additional 2-dimensional gels to visualize
proteins with a 10-fold difference in immunoreactivity for identification
by mass spectrometry. These identified proteins were then selected for
analysis in the present study.Statistical Analysis
Descriptive statistics were obtained, and receiver operating character-
istic curves (including area under the curve, specificity, and sensitivity)
were used to assess the difference among the 43 individual biomarkers us-
ing SPSS statistical software, version 18.0 (SPSS, Chicago, Ill). Fisher’s
exact and log-rank tests were used to determine significance between
the clinical factors (eg, age, gender, race, pack years of smoking exposure,
and histologic type) and recurrence. The Kruskal-Wallis test was used to
quantify the associations in biomarker concentrations between stage I
(with and without recurrence) and positive cohorts, and the Mann-
Whitney U and log-rank tests were used to determine the differences re-
lated to the interval to recurrence in stage I patients and overall survival.
All P values reported are 2-sided. The optimal multivariate panel of bio-
markers for predicting the clinical outcome was selected using variable se-
lection algorithms performed within the Random Forest package, as
previously described.6 In brief, the Random Forest multivariate method
grows numerous (1000 in the present study) cross-validated classification
trees for a panel of biomarkers, with each tree used to predict group mem-
bership for each case. These are counted as the tree ‘‘votes’’ for that
group. The forest chooses the group membership having the most votes
for all the 1000 trees in the forest. Each such tree is grown by cross-
validation, in which a training set (approximately two thirds of the values)
is randomly selected from the full data, and each tree is grown on this
training data to the largest extent possible (no pruning). The resultant
tree is then used to predict the group membership for the remaining val-
idation cases, termed an out-of-bag (OOB) prediction. This process is
then repeated 1000 times (ie, another training set is randomly selected
and a new tree is grown and used to perform another OOB prediction).
The classification accuracy of the Random Forest is measured by the av-
eraged error of the OOB predictions across the 1000 trees in the entire for-
est; this is termed the OOB error rate. The OOB error thus uses disjoint
subsets of the data for model fitting and validation repeatedly. The re-
ported sensitivity, specificity, and accuracy of the Random Forest method
are determined from these OOB predictions from the trees, averaged over
the 1000 trees in the forest.diovascular Surgery c Volume 144, Number 6 1345
TABLE 1. Demographics for stage I (AJCC 6th edition) patients
Variable Patients (n) Recurrence*
Interval to
recurrencey
Gender 0.76 0.5
Male 22 (42)
Female 30 (58)
Age 0.51z 0.52x
Range* (y) 50-83
69 y 27 (52)
>69 y 25 (48)
Smoking history 1.0 0.85
Smoker 45 (87)
Nonsmoker 7 (13)
Race 0.41 0.23
White 42 (81)
Black 9 (17)
Hispanic 1 (2)
Stage (6th edition)
Ia 18 (35)
Ib 34 (65)
pT1 18 (35)
pT2 34 (65)
Histologic subtype 0.28 0.27
Adenocarcinoma 29 (56)
SCC 16 (31)
NSCLC, other 7 (13)
Surgical resection
Lobectomy 40 (77)
Pneumonectomy 2 (4)
Segmentectomy
(with LN dissection)
10 (19)
Data in parentheses are percentages. AJCC, American Joint Committee on Cancer;
SCC, squamous cell carcinoma; NSCLC, non–small lung cancer; LN, lymph node.
*Fisher’s exact test. yLog-rank test. zLogistic regression analysis. xCox proportional
hazards regression analysis.
General Thoracic Surgery Rinewalt et al
G
T
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The demographic information for all stage I patients is
listed in Table 1. Median patient follow-up for the entire co-
hort was 40 months, with an average overall survival of
60.5, 35.2, and 28.2 months for the stage I (T1-T2N0M0) pa-
tients without recurrence, with recurrence, and lymph node-
positive disease (T1-T2N1-N2M0), respectively. After the
median 40 months of follow-up, 80% of stage I patients
without recurrence were still living compared with only
33% of stage I patients with recurrence and 37% of those
with node-positive disease. The median interval to recur-
rence for the stage I patients was 10.9 months. No signifi-
cant relationships were discovered between age, gender,
race, cancer histologic type, total pack-years smoking his-
tory, or PET standard uptake value for any incidence of
NSCLC recurrence or interval to recurrence in the stage I
cohorts using the Fisher exact test and log-rank test,
respectively.
Of the 15 stage I patients with known recurrence, there
was a slight female predominance (8/15), with most
patients undergoing lobectomy (11/15) or anatomic1346 The Journal of Thoracic and Cardiovascular Sursegmentectomy with node dissection (4/15). Most of these
patients had stage Ib (10/15), with the remaining having
stage Ia disease (5/15). No predominant histologic type
was noted, with adenocarcinoma (7/15), squamous cell car-
cinoma (3/15), and not otherwise specified (5/15) repre-
sented across this cohort.
Univariate analyses using receiver operating characteris-
tic curve parameters revealed 24 biomarkers with an area
under the curve greater than 0.6, with the Mann-Whitney
U test identifying 3 biomarkers associated with recurrence
in stage I patients (Table 2). Additional analyses evaluating
biomarker concentrations associated with recurrence in
the stage I patient cohort revealed 28 biomarkers significant
(P<.05) for recurrence using the log-rank test (Table 3).
Of these, TIMP-1 and autoantibodies against a-enolase,
ubiquilin, survivin, recoverin, peroxiredoxin, methylthioa-
denosine phosphorylase, protein disulfide isomerase 3
(PDIA3), phosphoglycerate dehydrogenase, and isocitrate
dehydrogenase were selected by the log-rank test as being
associated with the interval to recurrence (P<.01). More-
over, we also identified 21 biomarkers that were significant
(P<.01) in the stage I cohort in relation to overall survival
(Table 3), which included IGFBP-7 and IGFBP-2 and auto-
antibodies against peroxiredoxin, recoverin, and inosine-50-
monophosphate dehydrogenase. Univariate analysis
comparing stage I patients with recurrence and stage I pa-
tients with lymph node-positive disease using the Mann-
Whitney U test revealed 3 biomarkers with differences in
expression (receiver operating characteristic > 0.6;
P<.05), including IGFBP-5, IGFBP-7, and autoantibodies
against ubiquilin (Table 2).
Multivariate analysis for all stage I patients using the
Random Forest algorithm generated a 6-analyte panel con-
sisting of TIMP-1, IGFBP-4, and cytokeratin 19 fragment
21-1, along with autoantibodies against a-enolase, heat
shock protein A9, and PDIA3. This Random Forest-
generated panel accurately predicted 77% of stage I pa-
tients who developed recurrence (with cross-validation).
This panel provided 35 cases of true-negative findings,
6 cases of true-positive findings, and 2 cases of false-
positive findings in the 52 cases evaluated, for a sensitivity
of 74% and specificity of 79%. The area under the curve
was calculated as 0.786 (Figure 1).
In the present report, we adhered to the 6th edition of the
American Joint Committee on Cancer staging, because this
classification scheme reflects the system under which treat-
ment decisions for this cohort of patients was made. Inter-
estingly, 9 patients, all originally classified as having
stage 1b with the 6th edition would have been upstaged to
stage 2a or 2b using the 7th edition of the staging classifica-
tion system. Of these patients, 5 developed recurrence, with
3 having been misclassified by our panel. The removal of
these patients from the stage 1 cohort would improve our
accuracy to 79%.gery c December 2012
TABLE 2. Biomarkers evaluated in all patients
Biomarker
Stage I with recurrence vs LNþ Recurrence in stage I patients
P value* AUC P value* AUC
Autoantibodies
a-Enolase .168 0.566 .185 0.620
Annexin A1 (ANXA1) .145 0.557 .284 0.596
Annexin A2 (ANXA2) .439 0.524 .492 0.438
Calponin 2, isoform b (CNN) .208 0.556 .332 0.587
c-MYC (MYC) .106 0.588 .233 0.607
Endoplasmic reticulum protein 29 (ERP-29) .054 0.579 .106 0.645
Fumarate hydratase (FH) .723 0.505 .572 0.551
Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) .203 0.532 .131 0.636
Glyoxalase domain containing 4 (X-3 oxoacid) .203 0.564 .270 0.600
Heat shock protein A5 (HSPA5) .423 0.468 .170 0.623
Heat shock protein A9 (HSPA9) .106 0.520 .031 0.692
Hydroxacyl co-enzyme A dehydrogenase (HADH) .042 0.566 .094 0.650
Inosine-50-monophosphate dehydrogenase (IMPDH) .590 0.537 .777 0.474
Isocitrate dehydrogenase (IDH) .064 0.562 .082 0.656
Methyl thioadenosine phosphorylase (MTAP) .168 0.563 .244 0.605
NY-ESO .101 0.543 .086 0.654
p53 .823 0.438 .171 0.623
Peroxiredoxin (PER) .121 0.529 .060 0.668
Phosphoglycerate dehydrogenase (PHGDH) .039 0.558 .036 0.688
Phosphoglycerate mutase 1 (PGAM) .030 0.595 .146 0.631
Protein disulfide isomerase A3 (PDIA3) .152 0.500 .039 0.685
Recoverin (REC) .212 0.499 .094 0.650
Survivin .254 0.520 .261 0.602
Triose isomerase mutase (TIM) .138 0.546 .153 0.629
Ubiquilin .025 0.622 .140 0.632
Circulating factors
CA19-9 .354 0.547 .847 0.518
Cytokeratin 19 fragment (CYFRA 21-1) .674 0.555 .461 0.567
Insulin-like growth factor 1 (IGF-1) .365 0.507 .579 0.550
Insulin-like growth factor-binding protein 1 (IGFBP-1) .288 0.596 .298 0.594
Insulin-like growth factor-binding protein 2 (IGFBP-2) .053 0.662 .100 0.648
Insulin-like growth factor-binding protein 3 (IGFBP-3) .222 0.591 .413 0.574
Insulin-like growth factor-binding protein 4 (IGFBP-4) .803 0.442 .279 0.597
Insulin-like growth factor-binding protein 5 (IGFBP-5) .002 0.554 .173 0.623
Insulin-like growth factor-binding protein 6 (IGFBP-6) .365 0.519 .754 0.529
Insulin-like growth factor-binding protein 7 (IGFBP-7) .022 0.688 .499 0.561
Interferon (IFN)-g .266 0.518 .639 0.458
Interferon-g–induced protein 10 (IP-10) .198 0.627 .146 0.631
Interleukin-2 receptor-a (IL-2Ra) .248 0.579 .525 0.558
Monocyte colony-stimulating factor (M-CSF) .046 0.608 .553 0.553
Osteopontin .512 0.553 .606 0.453
Stromal cell-derived factor 1a (SDF-1a) .030 0.550 .064 0.666
Tissue inhibitor of metalloproteinase 1 (TIMP-1) .590 0.634 .307 0.593
LNþ, Lymph node-positive (disease); AUC, area under the curve. *Mann-Whitney rank sum (2-sided) test.
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SDISCUSSION
In the present study, we used proven multivariate classi-
fication models to develop a serum-based molecular prog-
nostication algorithm that predicts recurrence in stage
I NSCLC with greater sensitivity than current clinical
and pathologic staging technology. To this end, we formu-
lated a 6-analyte panel capable of predicting recurrence in
stage I NSCLC patients. This panel was generated fromThe Journal of Thoracic and Carperipherally circulating biomarkers with statistically
significant concentrations between the 2 stage I cohorts
(with and without recurrence). Biomarkers strongly related
to the interval to recurrence (P< .01) included TIMP-1
and autoantibodies against a-enolase, ubiquilin, survivin,
recoverin, peroxiredoxin, methylthioadenosine phosphory-
lase, PDIA3, phosphoglycerate dehydrogenase, and isoci-
trate dehydrogenase. Of these, the primary mechanisticdiovascular Surgery c Volume 144, Number 6 1347
TABLE 3. Median interval to recurrence and overall survival for stage I cohort
Biomarker
Interval to recurrence Overall survival
P value* Thresholdy Patients (n)  threshold P value Thresholdy Patients (n)  threshold
a-Enolasez <.001 1156 8 <.046 1156 8
PDIA3z .001 202 10 <.038 195 9
PERz .002 674 10 <.001 656 9
TIMP-1 .002 419 43 <.020 420 44
PHGDHz .004 145 8 <.056 531 40
Ubiquilinz .005 383 11 <.110 1749 42
MTAPz .006 573 8 <.209 1184 30
IDHz .006 306 15 <.123 767 38
Survivinz .008 1914 24 <.119 5020 42
RECz .010 659 11 <.002 571 10
HSPA9z .011 692 28 <.098 753 30
ERP-29z .011 144 9 <.039 640 44
X-3 oxoacidz <.012 602 12 <.285 1735 41
IP-10 <.014 294 20 <.090 484 38
GAPDHz <.014 3007 20 <.022 5701 38
IGFBP-2 <.015 11 16 <.007 14 19
p53z <.017 2997 33 <.019 2731 29
SDF-1a <.017 125 36 <.188 125 36
PGAMz <.019 528 40 <.077 530 41
HADHz <.023 653 41 <.026 768 43
ANXA1z <.024 552 41 <.102 511 39
IGFBP-7 <.025 42 9 <.003 60 43
IMPDHz <.031 532 8 <.008 1215 23
MYCz <.031 720 10 <.114 1210 17
IL-2Ra <.031 98 42 <.113 45 25
IGFBP-5 <.033 301 31 <.016 301 31
NYESOz <.038 545 9 <.016 523 8
HSPA5z <.043 962 27 <.050 1235 31
CNNz <.073 442 19 <.026 1607 42
CYFRA 21-1 <.077 999 41 <.101 649 32
TIMz <.091 768 11 <.015 590 9
FHz <.103 3220 27 <.119 2053 17
IGFBP-3 <.107 1058 40 <.308 904 18
IGFBP-4 <.108 197 32 <.387 247 38
M-CSF <.111 3 32 <.013 4 39
ANXA2z <.117 3131 37 <.070 1435 18
Osteopontin <.155 17 17 <.019 45 40
IGFBP-1 <.158 1 14 <.098 3 30
IFN-g <.163 6 11 <.320 21 23
SCF <.175 84 42 <.154 67 39
IGF-1 <.186 31 12 <.024 31 12
CA19-9 <.262 0 14 <.317 0 29
IGFBP-6 <.378 133 23 <.035 175 44
PDIA3, Protein disulfide isomerase A3; PER, peroxiredoxin; TIMP-1, tissue inhibitor of metalloproteinase 1; PHGDH, phosphoglycerate dehydrogenase; MTAP, methyl
thioadenosine phosphorylase; IDH, isocitrate dehydrogenase; REC, recoverin; HSPA9, heat shock protein A9; ERP-29, endoplasmic reticulum protein 29; IP-10, interferon-
g–induced protein 10; GAPDH, glyceraldehyde 3 phosphate dehydrogenase; IGFBP-2, insulin-like growth factor-binding protein 2; SDF-1a, stromal cell-derived factor 1a;
PGAM, phosphoglycerate mutase 1; HADH, hydroxacyl co-enzyme A dehydrogenase; ANXA1, annexin A1; IGFBP-7, insulin-like growth factor-binding protein 7; IMPDH,
inosine-50-monophosphate dehydrogenase; MYC, c-MYC; IL-2Ra, interleukin-2 receptor-a; IGFBP-5, insulin-like growth factor-binding protein 5; NYESO, NY-ESO;
HSPA5, heat shock protein A5; CNN, calponin 2, isoform b; CYFRA 21-1, cytokeratin 19 fragment; TIM, triose isomerase mutase; FH, fumarate hydratase; IGFBP-3, insu-
lin-like growth factor-binding protein 3; IGFBP-4, insulin-like growth factor-binding protein 4; M-CSF, monocyte colony-stimulating factor; ANXA2, annexin A2; IGFBP-1,
insulin-like growth factor-binding protein 1; IFN-g, interferon-g; IGF-1, insulin-like growth factor 1; IGFBP-6, insulin-like growth factor-binding protein 6. *Log-rank. yData
presented as median fluorescence intensity for autoantibodies and as pg/mL for factors. zAutoantibody assay.
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Spathways represented are apoptosis and tumor suppression
related (TIMP-1, survivin, and methylthioadenosine
phosphorylase), metabolism by way of the glycolytic or1348 The Journal of Thoracic and Cardiovascular Surtricarboxylic acid cycles (a-enolase and isocitrate dehydro-
genase), or protein synthesis and degradation (PGHDH,
PDIA3, and ubiquilin). Because only 1 biomarker,gery c December 2012
FIGURE 1. Receiver operating characteristic curve for 6-analyte algo-
rithm for predicting recurrence in stage I NSCLC patients. Area under
curve (AUC), 0.786, with sensitivity of 74% and specificity of 79%.
Rinewalt et al General Thoracic Surgery
G
T
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groups and the lymph node-positive patients (Table 2), these
markers were significant for recurrence alone and not
grossly residual disease missed by surgery or pathologic ex-
amination. Hypothetically, patients selected using a simple
and cost-effective serum test as having increased potential
for recurrence would subsequently be candidates for neoad-
juvant or adjuvant chemo- and/or radiotherapy and/or more
frequent imaging during postoperative surveillance. When
acted on early in the disease course, these additional inter-
ventions directed by the panel might shift the recurrence
survival curve in a more favorable direction. Alternatively,
this might also be a method to avoid unnecessary treatment
in this same cohort.
PET-CT imaging is the current method of choice for the
evaluation of metastatic progression before surgery and, for
the purposes of predicting recurrence in stage I NSCLC, had
performance characteristics of 74% sensitivity and 85%
specificity in 1 study.10 Also, positive findings in 2 other
studies showed that the maximum standard uptake value
of 5.5 or more11 or a standard uptake value of 4.7 or
greater12 was highly associated with recurrence. Although
PET-CT has a similar performance to our biomarker panel,
the vast difference in expense and exposure to radiation re-
main a concern for using PET-CT as a routine diagnostic
test. The bulk of the studies in the arena of prognostic mo-
lecular classifiers for stage I NSCLC have thus far focused
almost exclusively on the associations of gene expression
microarray profiles from the primary tumor with pathologic
lymph node status13-15 or clinical outcome16-18 (recently
reviewed by Lin and Beer19). Examples of some of theThe Journal of Thoracic and Carmore distinguished efforts able to accurately stratify pa-
tients with good versus poor outcomes include studies by
Raponi and colleagues,17 Shedden and colleagues,18 and
Mitra and colleagues.20 The most likely extension of these
studies is translation of the expression signature into a quan-
titative reverse transcriptase-polymerase chain reaction-
based assay for validation, with the intent of eventual
implementation in clinical laboratories. Most recently,
a 91-gene classifier algorithm was developed using 3 Affy-
metrix microarray data sets (n ¼ 680) and translated into
a quantitative real-time polymerase chain reaction assay
for predicting patient survival. Validation of this 91-gene
assay against 101 resected lung adenocarcinoma specimens
resulted in an overall accuracy of 73.4%.21 However, de-
spite the progress in this field, there has been some recent
controversy in the published data asserting that tumor het-
erogeneity might lead to skewed (sampling-related) molec-
ular profile information that, in turn, might provide
misleading prognostic information.22,23 We reason that
the evaluation of blood-based biomarkers for metastatic
progression would be less prone to misclassifications of
this type compared with tissue-based methods, given that
the peripheral blood represents an integrative matrix of total
tumor load and secondary tissues, with the latter possibly
leading to potential signal amplification, such as in
inflammation.
Our previous efforts in the development of multianalyte
serum biomarker panels in NSCLC include several reports
detailing the evolution of a serum test to accurately detect
lymph node progression in surgical patients.6,8,9 Our last
report presented a 6-analyte panel capable of classifying
nodal status in resectable NSCLC patients with a sensitivity
of 94%, a specificity of 97%, and an overall accuracy of
96%.8 As previously stated, for the present study, we rea-
soned that biomarkers capable of identifying patients with
disease progression to the locoregional lymph nodes might
also have utility in predicting recurrence in the stage I co-
hort. This hypothesis was based on the premise that occult
micrometastases are the primary cause of disease recur-
rence in this cohort, implicating metastatic processes as
a common mechanistic foundation to investigate. With
this rationale, we also included patients with pathologically
confirmed node-positive disease (pN1-N2) as ‘‘positive
controls’’ for our studies. Although the performance of
our ‘‘recurrence algorithm’’ (consisting of TIMP-1,
IGFBP-4, and cytokeratin 19 fragment 21-1 and autoanti-
bodies against a-enolase, heat shock protein A9, and
PDIA3) ultimately had a cross-validated 77% accuracy
for recurrence prediction and was not quite as robust as
our ‘‘nodal algorithm,’’ we are very confident in our ability
to further refine and improve this panel with our current ef-
forts with shotgun proteomics. The data agree with our gen-
eral hypothesis and show general trends of biomarker levels
for the stage I cohort being more similar to those of thediovascular Surgery c Volume 144, Number 6 1349
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Slymph node-positive patients than the balance of stage I pa-
tients without recurrence. Finally, 1 of the more prominent
studies on this topic was performed by D’Amico and col-
leagues24 who evaluated 171 patients with NSCLC with 7
serum biomarkers (vascular endothelial growth factor, he-
patocyte growth factor, E-selectin, CD44, basic fibroblast
growth factor, urokinase plasminogen activator, and uroki-
nase plasminogen activator receptor) using enzyme-linked
immunosorbent assay. This was accomplished against pre-
and postoperative (serial) blood sampling from patients un-
dergoing complete resection. The Cox proportional hazards
regression analysis showed disease recurrence could be pre-
dicted by decreasing levels of E-selectin (P¼ .002), increas-
ing levels of CD44 (P ¼ .001), and increasing levels of
urokinase plasminogen activator receptor (P¼ .03), with se-
rial sampling after surgery. A study is currently underway in
our laboratory to determinewhether the prognostic accuracy
of our current panel can be improvedwith the findings by the
D’Amico group and an effort to identify new biomarkers us-
ing proteomic methods. Furthermore, we will explore addi-
tional biomarkers for this purpose using both a shotgun
proteomics approach and an approach focused on identify-
ing surrogate biomarkers for the more prominent of the
metastasis-suppressor genes, including NM23, PEBP1,
and KAI1, as reviewed by Shoushtari and colleagues.25CONCLUSIONS
We have reported the development of a serum biomarker
panel for stage I NSCLC patients that predicts recurrence
previously undetected by standard imaging and pathologic
studies. The performance characteristics of this initial ‘‘re-
currence algorithm’’ (77% overall prognostic accuracy for
52 stage I NSCLC patients) were roughly in the same range
as those for PET-CT and quantitative real-time polymerase
chain reaction-based methods for predicting recurrence.
Additional refinement of this panel has the potential to ac-
curately stratify patients for more frequent screening proto-
cols or adjuvant therapy. With validation of this panel
against an external cohort, its true potential to improve
overall survival can be realized.References
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Dr Chuong D. Hoang (Stanford, Calif). I want to congratulate
you and your group on a provocative research effort, and, if your
ongoing work demonstrates that a blood-based test can accurately
predict disease recurrence in early-stage lung cancer, this could begery c December 2012
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San incredible opportunity to identify novel mechanistic insights to
lung cancer development and progression.
I have the following 2 questions based on your presentation.
First, the reasoning for your studies is that occult micrometastases
undetectable at surgery are the primary cause of disease recurrence
in early-stage lung cancer patients. With this in mind, why would
you want to collect blood samples for a predictive biomarker assay
in the preoperative period? The results of the blood assays could be
confounded by the presence of the primary tumor, which might ob-
scure the signal of the micrometastases. Why not collect the blood
samples in the postoperative period when the effects of the primary
tumor are no longer present?
Second, the primary method you used to select your predictive
analyses and the analytes was the Random Forest algorithm. This
classifier tends to work best when the number of input variables is
large, and yet you only tested 43 biomarkers for this study. What
were the selection criteria you used for including these potential
biomarkers? Also, this algorithm suffers sometimes from overfit-
ting of the data, which can lead to near-perfect classifier results,
and I noticed that you showed relatively lower sensitivity, specific-
ity, and accuracy in your final analysis.
Again, I really look forward to seeing your validation studies on
this interesting project. I thank you for the opportunity to discuss it.
Dr Rinewalt. Thank you, Dr Hoang, for your input and for your
questions.
To answer your first question, we chose to do these preopera-
tively because this was based on our previous discovery efforts.
We know that these tumor antigens typically fall into 3 categories:
aberrant isoforms of commonly expressed proteins, overexpres-
sion of common proteins, or proteins specific to the tumor itself,
the latter of which is what most of us are specifically interested
in targeting for either diagnosis or treatment. These are typically
only present in minuscule quantities, even from the primary tumor.
We hypothesized that wewould obtain a greater degree of sensitiv-
ity by doing assays at this time for the circulating autoantibodies to
the tumor instead of the tumor antigens directly, given the large
signal implication produced by the B cells of the body’s own hu-
moral response. Additionally, autoantibodies are thought to only
be produced early on in the disease process.
We selected these biomarkers for the study using 2 methods.
The first was based on reviews of the published data for biomarkers
that had previously demonstrated some efficacy for the early de-
tection of lung cancer. The second was based on our previous dis-
covery efforts in our laboratory, headed by Drs Michael Liptay and
Jeffrey Borgia. Specifically, we used Western blots prepared fromThe Journal of Thoracic and Cara lung adenocarcinoma cell line and then probed these with pooled
serum from non–small cell lung cancer patients, 1 without nodal
disease and 1 with nodal disease. We compared these and identi-
fied them using mass spectrometry to choose this list of
biomarkers.
To answer your questions about the Random Forest, it is a very
complicated multivariate statistical method. You are correct in that
it has been shown in the published data to be a robust and highly
accurate when one is analyzing data with a large number of inputs,
and we did have 43 biomarkers. Less noise is present when analyz-
ing this type of data. We believe that this will have resulted in less
overfitting of the data than, say, using just a classification tree, be-
cause the Random Forest will use approximately 1000 trees and
then average their results.
Dr Raphael Bueno (Boston, Mass). I congratulate you on your
paper.
I have 2 questions. One, you are looking for survivors versus pa-
tients likely to develop recurrence so you can affect treatment, so I
would expect your curves, the split curve, to look as a curve would
with survival at 5 years of 95% and a curve with survival of 20% at
5 years, which is really what you need achieve. Any comments on
that?
Second, we do not live in isolation. The pathologists have de-
fined, and we have defined, during the past 3 decades, as surgeons,
prognostic factors from studying the tumor, from the differentia-
tion, from the T status, for lymphovascular invasion, et cetera,
that are well established, and any prognostic test needs to be put,
as a part of that, in the context of that to bring an additional piece
of information. You do not merely want to recapitulate T1 versus
T2. Have you considered both issues?
Dr Rinewalt. Thank you for your comments, Dr Bueno.
To answer your first question, I agree that ultimately the goal is
to try to prognosticate these patients, and so we would hope that at
some point we will be able to develop a curve with which we can
predict who will develop recurrence and hopefully stratify them
into a new treatment that will shift that first curve up. The patients
who present with distant disease will probably continue to do
poorly; however, this was not the goal of our study. We are hoping
that by being able to intervene early on in the process that we can
shift that survival curve up.
To answer your second question, we have not specifically put
these together with all of the clinical factors, although I think ulti-
mately studying all the data that we have, including PET data, tu-
mor size, and histologic type, this will be a companion test and not
something that will stand alone.diovascular Surgery c Volume 144, Number 6 1351
